Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Takes First Step Towards "Track And Trace" As Final Guidance Lengthens Identifiers For Drug Packaging

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency had proposed an eight-digit system, but moved to 20 digits in final document after recommendation from PhRMA.

You may also be interested in...



Supply Chain Safety’s Dual Visions: Pedigree Or Just Serialization

As Congress considers how to ensure downstream supply chain security, industry groups are looking at a process to link drugs to their manufacturer. But in a recent communication with the Senate HELP Committee, FDA backs a “comprehensive national track-and-trace system.”

Track and Trace Standards Coming Shortly, FDA Says

Standards were required in FDAAA; industry asked for them in part to avoid conflicts with California pedigree law that will be implemented in 2015.

FDA Wants Authority To Enforce Track-And-Trace System For Drugs

Congress should empower FDA to enforce the track-and-trace standard for drugs that the agency already is tasked with developing, Deputy Commissioner for Global Regulatory Operations and Policy Deborah Autor told the Senate Health, Education, Labor and Pensions Committee Sept. 14.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel